Related Experiment Video
Updated: May 26, 2026

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
Published on: October 7, 2025
Non-coding RNAs for medical practice in oncology
Tetsuro Setoyama1, Hui Ling, Shoji Natsugoe
1Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abstract:
Alterations in microRNA (miRNA) and other short or long non-coding RNA (ncRNA) are involved in the initiation, progression, and metastasis of human cancer. The main molecular alterations result from variations in gene expression, which are usually minor but have consequences for a vast number of target protein-coding genes. The causes of the widespread differential expression of ncRNAs in malignant cells compared with normal cells can be explained by the location of these genes in genomic regions associated with cancer, by epigenetic mechanisms, and by alterations in the processing machinery. Expression profiling of human tumors based on the expression of miRNAs and other short or long ncRNAs has identified signatures associated with diagnosis, staging, progression, prognosis, and response to treatment. In addition, profiling has been exploited to identify ncRNAs that may represent downstream targets of activated oncogenic pathways or that target protein-coding genes involved in cancer. Recent studies found that miRNAs and non-coding ultraconserved genes are the main candidates for the elusive class of cancer-predisposing genes and that other types of ncRNAs participate in the genetic puzzle that gives rise to the malignant phenotype. These discoveries could be exploited for the development of useful markers for diagnosis and prognosis in cancer, as well as for the development of new RNA-based cancer therapies.
Insights
Alterations in non-coding RNAs (ncRNAs), including microRNAs (miRNAs), drive cancer development and metastasis. Profiling these ncRNAs offers new diagnostic markers and RNA-based cancer therapies.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- Non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), play crucial roles in human cancer, influencing initiation, progression, and metastasis.
- Differential expression of ncRNAs in cancer cells stems from genomic locations, epigenetic modifications, and altered processing machinery.
- These molecular alterations impact numerous target protein-coding genes, contributing to the malignant phenotype.
Purpose of the Study:
- To explore the involvement of ncRNAs in cancer development and metastasis.
- To investigate the potential of ncRNA expression profiling for cancer diagnosis, staging, prognosis, and treatment response.
- To identify novel ncRNAs as potential cancer-predisposing genes and therapeutic targets.
Main Methods:
- Expression profiling of human tumors using miRNA and other ncRNA data.
- Analysis of genomic regions, epigenetic mechanisms, and RNA processing machinery in cancer cells.
- Identification of ncRNAs targeting protein-coding genes or acting as downstream targets of oncogenic pathways.
Main Results:
- ncRNA expression signatures are associated with cancer diagnosis, staging, progression, prognosis, and treatment response.
- ncRNAs, including miRNAs and non-coding ultraconserved genes, are implicated as cancer-predisposing genes.
- ncRNAs are involved in the complex genetic landscape of cancer, contributing to the malignant phenotype.
Conclusions:
- ncRNA alterations are fundamental to human cancer pathogenesis.
- ncRNA expression profiling provides valuable biomarkers for cancer management.
- ncRNAs hold significant promise for the development of novel, RNA-based cancer therapies.
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
MicroRNAs
MicroRNAs
Abnormal Proliferation
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
